Recommendation of the President – Hympavzi (marstacimab)
On 20 March 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 36/2026 regarding the inclusion of the medicinal product Hympavzi (marstacimab) in the reimbursement program B.15, “Prevention of bleeding in children and adults with hemophilia A and B (ICD-10: D66, D67)”
Publication in Public Information Bulletin (BIP) >>